Polymer brush collapse under shear flow

Shear responsive surfaces offer potential advances in a number of applications. Surface functionalisation using polymer brushes is one route to such properties, particularly in the case of entangled polymers. We report on neutron reflectometry measurements of polymer brushes in entangled polymer solutions performed under controlled shear, as well as coarse-grained computer simulations corresponding to these interfaces. Here we show a reversible and reproducible collapse of the brushes, increasing with the shear rate. Using two brushes of greatly different chain lengths and grafting densities, we demonstrate that the dynamics responsible for the structural change of the brush are governed by the free chains in solution rather than the brush itself, within the range of parameters examined. The phenomenon of the brush collapse could find applications in the tailoring of nanosensors, and as a way to dynamically control surface friction and adhesion

Infrared Nonlinear Optics

Contains report on one research project.U. S. Air Force - Office of Scientific Research (Grant AFOSR-76-2894

Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study

This phase 2, double-blind, placebo-controlled, hypothesis-generating study evaluated the effects of oral reldesemtiv, a fast skeletal muscle troponin activator, in patients with spinal muscular atrophy (SMA). Patients ≥ 12 years of age with type II, III, or IV SMA were randomized into 2 sequential, ascending reldesemtiv dosing cohorts (cohort 1: 150 mg bid or placebo [2:1]; cohort 2: 450 mg bid or placebo [2:1]). The primary objective was to determine potential pharmacodynamic effects of reldesemtiv on 8 outcome measures in SMA, including 6-minute walk distance (6MWD) and maximum expiratory pressure (MEP). Changes from baseline to weeks 4 and 8 were determined. Pharmacokinetics and safety were also evaluated. Patients were randomized to reldesemtiv 150 mg, 450 mg, or placebo (24, 20, and 26, respectively). The change from baseline in 6MWD was greater for reldesemtiv 450 mg than for placebo at weeks 4 and 8 (least squares [LS] mean difference, 35.6 m [p = 0.0037] and 24.9 m [p = 0.058], respectively). Changes from baseline in MEP at week 8 on reldesemtiv 150 and 450 mg were significantly greater than those on placebo (LS mean differences, 11.7 [p = 0.038] and 13.2 cm H2O [p = 0.03], respectively). For 6MWD and MEP, significant changes from placebo were seen in the highest reldesemtiv peak plasma concentration quartile (Cmax \u3e 3.29 μg/mL; LS mean differences, 43.3 m [p = 0.010] and 28.8 cm H2O [p = 0.0002], respectively). Both dose levels of reldesemtiv were well tolerated. Results suggest reldesemtiv may offer clinical benefit and support evaluation in larger SMA patient populations

Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure

Background: Omecamtiv mecarbil (OM) is a selective cardiac myosin activator that increases myocardial function in healthy volunteers and in patients with chronic heart failure. Objectives: This study evaluated the pharmacokinetics, pharmacodynamics, tolerability, safety, and efficacy of OM in patients with acute heart failure (AHF). Methods: Patients admitted for AHF with left ventricular ejection fraction ≤40%, dyspnea, and elevated plasma concentrations of natriuretic peptides were randomized to receive a double-blind, 48-h intravenous infusion of placebo or OM in 3 sequential, escalating-dose cohorts. Results: In 606 patients, OM did not improve the primary endpoint of dyspnea relief (3 OM dose groups and pooled placebo: placebo, 41%; OM cohort 1, 42%; cohort 2, 47%; cohort 3, 51%; p = 0.33) or any of the secondary outcomes studied. In supplemental, pre-specified analyses, OM resulted in greater dyspnea relief at 48 h (placebo, 37% vs. OM, 51%; p = 0.034) and through 5 days (p = 0.038) in the high-dose cohort. OM exerted plasma concentration-related increases in left ventricular systolic ejection time (p < 0.0001) and decreases in end-systolic dimension (p < 0.05). The adverse event profile and tolerability of OM were similar to those of placebo, without increases in ventricular or supraventricular tachyarrhythmias. Plasma troponin concentrations were higher in OM-treated patients compared with placebo (median difference at 48 h, 0.004 ng/ml), but with no obvious relationship with OM concentration (p = 0.95). Conclusions: In patients with AHF, intravenous OM did not meet the primary endpoint of dyspnea improvement, but it was generally well tolerated, it increased systolic ejection time, and it may have improved dyspnea in the high-dose group. (Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure [ATOMIC-AHF]; NCT01300013)

Infrared Nonlinear Optics

Contains research objectives and summary of research on one research project.U. S. Air Force - Office of Scientific Research (Grant AFOSR-76-2894

Comparison of In-Situ, Model and Ground Based In-Flight Icing Severity

As an aircraft flies through supercooled liquid water, the liquid freezes instantaneously to the airframe thus altering its lift, drag, and weight characteristics. In-flight icing is a contributing factor to many aviation accidents, and the reliable detection of this hazard is a fundamental concern to aviation safety. The scientific community has recently developed products to provide in-flight icing warnings. NASA's Icing Remote Sensing System (NIRSS) deploys a vertically--pointing Ka--band radar, a laser ceilometer, and a profiling multi-channel microwave radiometer for the diagnosis of terminal area in-flight icing hazards with high spatial and temporal resolution. NCAR s Current Icing Product (CIP) combines several meteorological inputs to produce a gridded, three-dimensional depiction of icing severity on an hourly basis. Pilot reports are the best and only source of information on in-situ icing conditions encountered by an aircraft. The goal of this analysis was to ascertain how the testbed NIRSS icing severity product and the operational CIP severity product compare to pilot reports of icing severity, and how NIRSS and CIP compare to each other. This study revealed that the icing severity product from the ground-based NASA testbed system compared very favorably with the operational model-based product and pilot reported in-situ icing

Workshop to identify critical windows of exposure for children's health: cancer work group summary.

We considered whether there are discrete windows of vulnerability in the development of cancer and which time periods may be of the greatest importance. Cancer was considered broadly, including cancers in childhood as well as adult cancers that may have an in utero or childhood origin. We concluded that there was evidence from animal and epidemiologic studies for causal relationships for preconceptional, in utero, and childhood exposures and cancer occurrence in children and adults. However, the evidence is incomplete and all relevant critical windows may not have been identified. The comprehensive evaluation of the relative importance of specific time windows of exposure is limited. Improvements in the design of epidemiologic studies and additional animal studies of mechanisms are warranted

Monitoring the US ATLAS Network Infrastructure with perfSONAR-PS

Global scientific collaborations, such as ATLAS, continue to push the network requirements envelope. Data movement in this collaboration is routinely including the regular exchange of petabytes of datasets between the collection and analysis facilities in the coming years. These requirements place a high emphasis on networks functioning at peak efficiency and availability; the lack thereof could mean critical delays in the overall scientific progress of distributed data-intensive experiments like ATLAS. Network operations staff routinely must deal with problems deep in the infrastructure; this may be as benign as replacing a failing piece of equipment, or as complex as dealing with a multi-domain path that is experiencing data loss. In either case, it is crucial that effective monitoring and performance analysis tools are available to ease the burden of management. We will report on our experiences deploying and using the perfSONAR-PS Performance Toolkit at ATLAS sites in the United States. This software creates a dedicated monitoring server, capable of collecting and performing a wide range of passive and active network measurements. Each independent instance is managed locally, but able to federate on a global scale; enabling a full view of the network infrastructure that spans domain boundaries. This information, available through web service interfaces, can easily be retrieved to create customized applications. The US ATLAS collaboration has developed a centralized “dashboard” offering network administrators, users, and decision makers the ability to see the performance of the network at a glance. The dashboard framework includes the ability to notify users (alarm) when problems are found, thus allowing rapid response to potential problems and making perfSONAR-PS crucial to the operation of our distributed computing infrastructure.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/98635/1/1742-6596_396_4_042038.pd

A Phase III Trial of Tirasemtiv as a Potential Treatment for Amyotrophic Lateral Sclerosis

Objective: To assess the efficacy of tirasemtiv, a fast skeletal muscle troponin activator, vs. placebo in patients with amyotrophic lateral sclerosis. Methods: VITALITY-ALS (NCT02496767) was a multinational, double-blind, randomized, placebo-controlled clinical trial. Participants tolerating 2 weeks of open-label tirasemtiv (125 mg twice daily) were randomized 3:2:2:2 to placebo or one of three target tirasemtiv dose levels, using an escalating dosage protocol lasting 28 days. The primary outcome measure was changed in slow vital capacity (SVC) at 24 weeks. Secondary endpoints included a change in muscle strength and time to respiratory milestones of disease progression. Results: Of 744 participants, 565 tolerated open-label tirasemtiv and received randomized treatment. By 24 weeks, 23 (12.2%) placebo-treated participants discontinued study treatment vs. 129 (34.2%) randomized to tirasemtiv. SVC declined by 14.4% (95% CI: ˆ’16.8, ˆ’11.9) in the placebo group and 13.4% (95% CI: ˆ’15.3, ˆ’11.6) in the tirasemtiv group (p = 0.56). Secondary endpoints did not show significant differences. However, participants who tolerated tirasemtiv at their randomized dose showed a numeric trend toward a dose-related slowing of decline in SVC (p = 0.11). Dizziness, fatigue, nausea, weight loss, and insomnia occurred more frequently on tirasemtiv. Serious adverse events were similar across groups. Conclusions: Tirasemtiv did not alter the decline of SVC or significantly impact secondary outcome measures. Poor tolerability of tirasemtiv may have contributed to this result. However, participants tolerating their intended dose exhibited a trend toward treatment benefit on SVC, suggesting the underlying mechanism of action may still hold promise, as is being tested with a different fast skeletal muscle troponin activator (NCT03160898)

MiToS and King\u27s staging as clinical outcome measures in ALS: A retrospective analysis of the FORTITUDE-ALS trial

OBJECTIVE: To evaluate the Milano-Torino staging (MiToS) and King\u27s staging systems as potential outcome measures for clinical trials in amyotrophic lateral sclerosis (ALS) by assessing these outcomes in FORTITUDE-ALS. METHODS: This was a RESULTS: The full analysis set consisted of 456 patients randomized 3:1 ( CONCLUSION: This exploratory analysis showed the feasibility of MiToS and King\u27s staging as potential outcome measures in ALS. Additional studies of these staging systems are needed to further explore their utility in ALS clinical trials